Chemoimmunotherapy With a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome in De Novo Philadelphia Chromosome–Negative Precursor B-Lineage Acute Lymphoblastic Leukemia

Aberrant Underexpression of CD81 in Precursor B-Cell Acute Lymphoblastic Leukemia

(2009) Tariq Muzzafar et al.   AMERICAN JOURNAL OF CLINICAL PATHOLOGY

Ofatumumab, a second-generation anti-CD20 monoclonal antibody, for the treatment of lymphoproliferative and autoimmune disorders

(2009) Jorge Castillo et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Adverse prognostic significance of CD20 expression in adults with Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia

(2009) S. Maury et al.   HAEMATOLOGICA

Monoclonal Antibody Therapy with Rituximab for Acute Lymphoblastic Leukemia

(2009) Deborah A. Thomas et al.   HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA

CD20 up-regulation in pediatric B-cell precursor acute lymphoblastic leukemia during induction treatment: setting the stage for anti-CD20 directed immunotherapy

(2008) M. N. Dworzak et al.   BLOOD

Prognostic significance of CD20 expression in adults with de novo precursor B-lineage acute lymphoblastic leukemia

(2008) D. A. Thomas et al.   BLOOD

Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia

(2008) C. S. Tam et al.   BLOOD

Durable complete responses from therapy with combined epratuzumab and rituximab

(2008) John P. Leonard et al.   CANCER

Acquirement of Rituximab Resistance in Lymphoma Cell Lines Is Associated with Both Global CD20 Gene and Protein Down-Regulation Regulated at the Pretranscriptional and Posttranscriptional Levels

(2008) M. S. Czuczman et al.   CLINICAL CANCER RESEARCH